Friday November 20th, 2015 6:15 pm – 7:45 pm
Hilton Universal City, Los Angeles
555 Universal Hollywood Dr, Universal City, CA 91608
The program will intersperse panel discussions with didactic lectures,
leaving time for Q +A and Audience participation throughout the activity
The overall objectives of this CME program are to examine the prevalence and management of CVD in the high-risk patient. Review the role of LDL-C in the Development of Atherosclerosis. Appreciate the function of PCSK9 in LDL Homeostasis following its journey from discovery to clinical practice. Provide an update on pharmacological strategies to reduce cardiovascular disease risk. Follow the development of PCSK9 inhibitors know their efficacy and safety and understand their implication to practice. Addressing medical society’s guidelines and incorporating expert insights on the potential role of PCSK9i in lipid management and impact on treatment target goals to achieve better patient outcomes.
Recognize the challenges of the high-risk person and the role of LDL and other lipid disorders in the development of atherosclerosis. Understand the mechanism of LDL production and the role of PCSK9 in homeostasis of LDL-C. Be knowledgeable of the development of monoclonal antibodies, the PCSK9i for the management of LDL-C in clinical practice know their efficacy and safety. Highlight and discuss the potential role and implication the PCSK9i as part of a comprehensive management plan of the high risk patient for CVD.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the accreditation council for Continuing Medical Education through the joint providership of PESI, Inc and Metabolic Endocrine Education Foundation (MEEF). PESI, Inc is accredited by the ACCME to provide continuing medical education for physicians. The PESI, Inc designated this live educational activity for a maximum of 1.5 AM PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.
For information please contact: email@example.com or (818)342-1889